CIM Investment Management’s Epizyme, Inc EPZM Stock Holding History

CIM Investment Management’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-11,485	Closed	-$197K	–	378
2017 Q1	$197K	Hold	11,485	–	–	0.07%	342
2016 Q4	$139K	Hold	11,485	–	–	0.05%	341
2016 Q3	$113K	Buy	11,485 +430	+4%	+$3.92K	0.04%	338
2016 Q2	$113K	Buy	+11,055	New	+$123K	0.05%	285

Other funds holding EPZM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

CIM Investment Management's EPZM Position: Q2 2017 in Review

CIM Investment Management sold out of Epizyme, Inc (EPZM) in Q2 2017, closing a stake of 11,485 shares — an estimated $197K sold.

CIM Investment Management first reported a position in EPZM in Q2 2016 and held it in 4 quarters. The position peaked at $197K in Q1 2017. 108 funds tracked by Wall St. Rank hold EPZM as of Q2 2017.

CIM Investment Management reported no remaining Epizyme, Inc position as of Q2 2017 after selling out during the quarter.
CIM Investment Management sold 11,485 Epizyme, Inc shares in Q2 2017, an estimated $197K.
CIM Investment Management first reported a position in Epizyme, Inc in Q2 2016 and held it in 4 quarters.
CIM Investment Management's Epizyme, Inc position peaked at $197K in Q1 2017.
108 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2017.

Based on CIM Investment Management's 13F filing for Q2 2017, filed 8 Aug 2017.